HUHaruki Ujiie

Haruki Ujiie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haruki Ujiie has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Naoyuki Nishiya

    Division of Integrated Information for Pharmaceutical Sciences, Department of Clinical Pharmacy, School of Pharmacy Iwate Medical University Shiwa‐gun Iwate Japan

    3 shared publications
  • Honami Yonezawa

    Division of Health Chemistry, Department of Clinical Pharmaceutical Sciences, School of Pharmacy Iwate Medical University Shiwa‐gun Iwate Japan

    2 shared publications
  • Akari Ikeda

    Ōmura Satoshi Memorial Institute and Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Minato-ku 108-8641, Japan

    1 shared publication
  • Ami Yamamoto

    Division of Integrated Information for Pharmaceutical Sciences, Department of Clinical Pharmacy, School of Pharmacy, Iwate Medical University, Iwate, Japan

    1 shared publication
  • Ayana Sasaki

    Division of Integrated Information for Pharmaceutical Sciences, Department of Clinical Pharmacy, School of Pharmacy, Iwate Medical University, Iwate, Japan

    1 shared publication
  • Haruka Endo

    Division of Integrated Information for Pharmaceutical Sciences, Department of Clinical Pharmacy, Iwate Medical University School of Pharmacy, Shiwa-gun, Yahaba-cho, Iwate 028-3694, Japan

    1 shared publication

Latest Publications

  • Open Access

    Machine Learning–Driven Integration of Cancer Cell Phenotypes Predicts Cisplatin Sensitivity

    by Haruki Ujiie, Tomoko Sakyo, Konomi Oya, Yuto Sugawara, Miyu Ota, Honami Yonezawa, Naoyuki Nishiya

    Background: Precision medicine has personalized anticancer therapies and has been considered standard practice. Although current cancer genomic profiling tests are powerful tools to predict the efficacy of molecular targeted drugs or immune checkpoint inhibitors, they are not readily applicable for classical anticancer agents. In this study, we report a novel concept of phenotype‐based classification using machine learning analysis of gene expression patterns to predict the effectiveness of anticancer agents. Methods: Hierarchical clustering of IC 50 values distinguished cisplatin‐sensitive and resistant cell lines. Differentially expressed gene (DEG) analysis and SHAP value‐based machine learning identified 26 key genes, and the cisplatin sensitivity predictor using 26 genes (CSP26G) model was developed. Results: Cisplatin‐resistant A549CR cells experimentally confirmed the external validity of the CSP26G model. The model also classified patients with non‐small cell lung cancer in The Cancer Genome Atlas (TCGA) clinical database into cisplatin‐sensitive and cisplatin‐resistant groups. The predicted sensitive group showed significantly longer survival than the predicted resistant group. Furthermore, CSP26G predicts not only cisplatin efficacy but also responsiveness to other DNA‐damaging agents. Conclusion: These findings indicate that the sensitivity prediction model constructed through the integration of DEG and machine learning analyses can forecast drug sensitivity, thereby contributing to the advancement of effective and personalized precision medicine in classical chemotherapies.


  • Dexamethasone reduces cisplatin-induced hair cell damage by inducing cisplatin resistance through metallothionein-2

    by Haruki Ujiie, Naoyuki Nishiya, Ami Yamamoto, Takeru Takada, Megumi Onodera, Ayana Sasaki, Takuya Oikawa

    Purpose Hair cell damage is a common side effect caused by the anticancer drug cisplatin (CDDP), which reduces patient quality of life. One CDDP resistance mechanism that occurs in recurrent cancers is heavy metal detoxification by metallothionein-2 (mt2). Here, we show that in zebrafish larvae, dexamethasone (DEX) reduces CDDP-induced hair cell damage by enhancing mt2 expression. Methods Transgenic zebrafish (cldn: gfp; atoh1: rfp) that express green and red fluorescent proteins in neuromasts and hair cells, respectively, were used. The zebrafish were pretreated with DEX at 52 h post-fertilization (hpf) for 8 h, followed by CDDP treatment for 12 h. The lateral line hair cells of CDDP-treated zebrafish at 72 hpf were observed by fluorescence microscopy. Results Reporting odds ratio (ROR) analysis using an adverse event database indicated an association between a decrease in CDDP-induced ototoxicity and DEX as an antiemetic treatment for cancer chemotherapy. Pretreatment with DEX protected 72 hpf zebrafish hair cells from CDDP-induced damage. The expression of mt2 mRNA was significantly increased by the combination of 10 µM DEX with CDDP. Gene editing of mt2 reversed the protective effect of DEX against CDDP-induced damage in hair cells. Conclusion DEX protects hair cells from CDDP-induced damage through increased mt2 expression, which is a resistance mechanism for platinum-based anticancer drugs.


  • Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study

    by Hiroaki Takahashi, Yoko Saito, Kanon Sugawara, Masaki Sato, Tomohiko Tairabune, Haruki Ujiie, Junichi Asaka, Kenzo Kudo

    Purpose Acneiform rash is frequently observed in patients undergoing cancer treatment with anti-epidermal growth factor receptor (EGFR) antibody drugs and can often necessitate treatment discontinuation. However, the specific changes in skin parameters resulting from anti-EGFR antibody drug administration are poorly understood. Therefore, this study aimed to longitudinally and quantitatively evaluate the changes in skin parameters (transepidermal water loss [TEWL], hydration level, and sebum level) caused by anti-EGFR antibody drugs and investigate their potential as control markers for skin disorders. Methods This prospective study included 12 patients with colorectal cancer who received anti-EGFR antibody drugs for the first time. The assessment items included the grade of acneiform rash and skin parameters (TEWL, hydration level, and sebum level), which were observed for up to 6 weeks after administration of the medication. Results The enrolled patients were classified into two groups based on the grade of acneiform rash caused by anti-EGFR antibody drugs: “Grade 1 and lower,” and “Grade 2 and higher.” The skin parameters were compared between these groups. The results showed that in the “Grade 2 and higher” group, TEWL in the face (at week 2 of administration), chest (baseline, weeks 2 and 6 of administration), and back (at week 2 of administration) were significantly higher than those in the “Grade 1 and lower” group. However, the two groups showed no significant differences in hydration or sebum levels at any time point. Conclusion TEWL can serve as a marker for acneiform rashes induced by anti-EGFR antibody drugs during cancer treatment.


  • Open Access

    Ivermectin represses Wnt/β-catenin signaling by binding to TELO2, a regulator of phosphatidylinositol 3-kinase-related kinases

    by Honami Yonezawa, Akari Ikeda, Ryo Takahashi, Haruka Endo, Yasuyo Sugawara, Mikako Goto, Mirute Kanno, Sosuke Ogawa, Karin Nakamura, Haruki Ujiie, et al.